- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06170944
Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke (RICAS)
February 21, 2024 updated by: Hui-Sheng Chen, General Hospital of Shenyang Military Region
Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke (RICAS): a Prospective, Randomized, Blind Endpoint, Multicenter Study
The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Stroke is the second leading cause of death and the third leading cause of death and disability combined in the world.
The remote ischemic preconditioning (RIC) procedure is low-cost with excellent properties of safety, tolerability and feasibility in both AIS and cardiovascular diseases.
In this study, we aim to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.
The RICAS study is a prospective, randomized, blind endpoint, multicenter study.
Eligible patients with ischemic stroke of anterior circulation with large artery atherosclerosis etiology, poor collateral compensation, and more than 1 month of the symptom onset, are randomly assigned into the experimental group and control group with a ratio of 1:1.
The patients in experiment group will receive treatment with RIC for 1 year as an adjunct to guideline-based treatment, while patients in control group only receive guideline-based treatment.
The primary outcome is proportion of collateral status improvement, which is defined as an increase of ASITN/SIR score of 1 or more assessed on DSA at 12 months after randomization.
The safety outcomes include RIC-related adverse events.
A maximum of 300 patients (150 participants per group) are required to test the superiority hypothesis with 80% power (using a two-sided α = 0.05) to detect the 15% difference.
The primary endpoint will further be stratified by age, gender, inclusion event (acute ischemic stroke ore transient ischemic stroke), tandem lesion, history of hypertension, hypercholesterolemia, diabetes mellitus, ischemic stroke, transient ischemic attack, and myocardial infarction.
This study will provide the direct evidence for improvement of collateral status by chronic RIC treatment.
Study Type
Interventional
Enrollment (Estimated)
300
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ziai Zhao
- Phone Number: 18304098115
- Email: zhaoziai@hotmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 1. Age over 40 years old;
- 2. Diagnosed with ischemic stroke (including TIA and cerebral infarction), with onset time of more than 1 month;
- 3. Culprit arteries are the large arteries of the anterior circulation with atherosclerotic stenosis (≥50%) or occlusion;
- 4. ASITN/SIR collateral circulation of 0-3 based on DSA evaluation;
- 5. First onset or prior onset with no significant sequelae (mRS ≤ 2);
- 6. Those who are not expected to undergo angioplasty within 12 months (judged by the doctor or decided by patients and/or their representatives);
- 7. The availability of informed consent.
Exclusion Criteria:
- 1) Patients with severe infection or serious diseases such as liver, kidney, hematopoietic system, endocrine system, etc.;
- 2) Patients with a history of stroke and severe sequelae (mRS≥3);
- 3) arterial stenosis due to aortic dissection, moyamoya disease; Any known vasculitic disease; herpes zoster, varicella-zoster or other viral infections with vascular lesions; neurosyphilis; other intracranial infections; any intracranial artery stenosis associated with hypercytosis of cerebrospinal fluid; radiation-induced vascular lesions; myofiber dysplasia; sickle cell disease; neurofibromas; benign vascular lesions of the central nervous system; postpartum vascular disease; stenosis of the intracranial arteries due to vasospasm or thrombosm;
- 4) Uncontrolled severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110 mmHg after drug treatment) ;
- 5) Subclavian artery stenosis ≥50% or subclavian artery steal syndrome;
- 6) Patients with intracranial hemorrhage (parenchymal hemorrhage, subarachnoid hemorrhage, subdural/epidural hemorrhage) within 90 days before enrollment;
- 7) Intracranial tumor, arteriovenous malformation, or aneurysm;
- 8) Patients with severe hematologic diseases or severe coagulation abnormalities;
- 9) Retinal hemorrhage or visceral hemorrhage within 30 days;
- 10) Those who are expected to undergo major surgery (including femoral artery, cardiac, aortic or carotid artery surgery) within 30 days before enrollment or within 12 months after enrollment;
- 11) Those who have received stent implantation, angioplasty or other related medical devices for the target diseased blood vessels, or those who are expected to undergo the above treatments within 12 months after enrollment;
- 12) Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.
- 13) Damage and lesions in the cerebral veins;
- 14) Pregnant or lactating women;
- 15) Those who are participating in other clinical trials within 3 months;
- 16) Life expectancy is less than 1 year
- 17) Patients not suitable for this clinical studies considered by researcher
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remote ischemic preconditioning and guideline-based treatment
5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), once or twice daily for 12 months.
|
The patients in experiment group will receive treatment with RIC (5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg) for 1 year as an adjunct to guideline-based treatment.
|
No Intervention: Guideline-based treatment
Guideline-based treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of collateral status improvement.
Time Frame: 12 months
|
collateral status improvement is defined as an increase of ASITN/SIR score of 1 or more assessed on DSA at 12 months after randomization.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The influence of RIC to neurological functions
Time Frame: 12 months
|
Neurological functions was determined by modified Rankin Scale score (0-42, higher scores mean a worse outcome )
|
12 months
|
Recurrence of nonfatal ischemic stroke in 12 months
Time Frame: 12 months
|
Ischemic stroke is diagnosed based on clinical symptom and neuroimaging
|
12 months
|
Composite vascular events
Time Frame: 12 months
|
Composite vascular events include stroke, myocardial infarction, vascular death
|
12 months
|
Influence on heart function
Time Frame: 12 months
|
heart function is assessed by cardiac ultrasound, electrocardiogram, myocardial enzyme profile, etc
|
12 months
|
Influence on kidney function
Time Frame: 12 months
|
kidney function is assessed by glomeruar filtration rate
|
12 months
|
RIC-related adverse events
Time Frame: 12 months
|
include local pain, intolerance, etc.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
November 30, 2025
Study Completion (Estimated)
January 30, 2026
Study Registration Dates
First Submitted
December 5, 2023
First Submitted That Met QC Criteria
December 13, 2023
First Posted (Actual)
December 14, 2023
Study Record Updates
Last Update Posted (Actual)
February 23, 2024
Last Update Submitted That Met QC Criteria
February 21, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Y(2023)169
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data dictionary.
IPD Sharing Time Frame
With publication.
IPD Sharing Access Criteria
Researchers whose proposed use of the data has been approved.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke, Ischemic
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, Brazil, France, Slovakia, ... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Remote ischemic preconditioning
-
Tartu University HospitalCompletedAtherosclerosis | Stable Angina | Peripheral Artery Disease | Contrast-induced NephropathyEstonia
-
St. Francis Hospital, New YorkTerminatedCoronary Artery DiseaseUnited States
-
Capital Medical UniversityPeking University First HospitalCompletedCerebral Small Vessel DiseaseChina
-
Azienda Ospedaliera Città della Salute e della...CompletedAcute Kidney InjurySpain, France, Italy
-
Medical University of LodzCompletedRemote Ischemic Preconditioning | Contrast Induced - Acute Kidney InjuryPoland
-
Ulsan University HospitalCompletedContrast Induced Acute Kidney InjuryKorea, Republic of
-
Università Vita-Salute San RaffaeleRecruitingMyocardial Ischemia | SurgeryItaly, Russian Federation, Serbia
-
St. Josefs-Hospital Wiesbaden GmbHRecruitingAtrial FibrillationGermany
-
Institut für Pharmakologie und Präventive MedizinWithdrawnEffectivity of RIPC in Outcomes of TAVI ProcedureGermany